BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 2017;3:212-32. [PMID: 28691103 DOI: 10.18053/jctres.03.2017S1.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Skinner CM, Miousse IR, Ewing LE, Sridharan V, Cao M, Lin H, Williams DK, Avula B, Haider S, Chittiboyina AG, Khan IA, ElSohly MA, Boerma M, Gurley BJ, Koturbash I. Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments. Food Chem Toxicol 2018;122:21-32. [PMID: 30282009 DOI: 10.1016/j.fct.2018.09.067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Imran M, Sergent O, Tête A, Gallais I, Chevanne M, Lagadic-Gossmann D, Podechard N. Membrane Remodeling as a Key Player of the Hepatotoxicity Induced by Co-Exposure to Benzo[a]pyrene and Ethanol of Obese Zebrafish Larvae. Biomolecules 2018;8:E26. [PMID: 29757947 DOI: 10.3390/biom8020026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chang GR, Liu HY, Yang WC, Wang CM, Wu CF, Lin JW, Lin WL, Wang YC, Lin TC, Liao HJ, Hou PH, Chan CH, Lin CF. Clozapine Worsens Glucose Intolerance, Nonalcoholic Fatty Liver Disease, Kidney Damage, and Retinal Injury and Increases Renal Reactive Oxygen Species Production and Chromium Loss in Obese Mice. Int J Mol Sci 2021;22:6680. [PMID: 34206460 DOI: 10.3390/ijms22136680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Huang S, Liu M, Fu F, Liu H, He B, Xiao D, Yang J. High Serum Estradiol Reduces Acute Hepatotoxicity Risk Induced by Epirubicin Plus Cyclophosphamide Chemotherapy in Premenopausal Women with Breast Cancer. Front Pharmacol 2020;11:572444. [PMID: 33584258 DOI: 10.3389/fphar.2020.572444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Boeckmans J, Rodrigues RM, Demuyser T, Piérard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? Arch Toxicol 2020;94:1367-9. [PMID: 32266419 DOI: 10.1007/s00204-020-02734-1] [Cited by in F6Publishing: 50] [Reference Citation Analysis]
6 Perkins EJ, Ashauer R, Burgoon L, Conolly R, Landesmann B, Mackay C, Murphy CA, Pollesch N, Wheeler JR, Zupanic A, Scholz S. Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment. Environ Toxicol Chem 2019;38:1850-65. [PMID: 31127958 DOI: 10.1002/etc.4505] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
7 Taneva G, Dimitrov D, Velikova T. Liver dysfunction as a cytokine storm manifestation and prognostic factor for severe COVID-19. World J Hepatol 2021; 13(12): 2005-2012 [DOI: 10.4254/wjh.v13.i12.2005] [Reference Citation Analysis]
8 Jang Y, Lee JY, Kim SU, Kim B. A qualitative study of self-management experiences in people with non-alcoholic fatty liver disease. Nurs Open 2021;8:3135-42. [PMID: 34405583 DOI: 10.1002/nop2.1025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Alfani R, Vassallo E, De Anseris AG, Nazzaro L, D'Acunzo I, Porfito C, Mandato C, Vajro P. Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease. Children (Basel) 2018;5:E169. [PMID: 30551665 DOI: 10.3390/children5120169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
11 Moles A, Torres S, Baulies A, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial-Lysosomal Axis in Acetaminophen Hepatotoxicity. Front Pharmacol 2018;9:453. [PMID: 29867464 DOI: 10.3389/fphar.2018.00453] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
12 Massart J, Begriche K, Corlu A, Fromenty B. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease. IJMS 2022;23:1062. [DOI: 10.3390/ijms23031062] [Reference Citation Analysis]
13 Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, Farsi Y, Nasiri MJ. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne) 2021;8:731436. [PMID: 34616757 DOI: 10.3389/fmed.2021.731436] [Reference Citation Analysis]
14 Ferron PJ, Gicquel T, Mégarbane B, Clément B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Biochimie 2020;179:266-74. [PMID: 32891697 DOI: 10.1016/j.biochi.2020.08.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 APASL Covid-19 Task Force. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415-428. [PMID: 32447721 DOI: 10.1007/s12072-020-10054-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
16 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mitchell NE, Harner W, Laczek J. β-Blocker-Induced Liver Injury: A Class Effect With Incidental Rechallenge. ACG Case Rep J 2019;6:e00273. [PMID: 32309473 DOI: 10.14309/crj.0000000000000273] [Reference Citation Analysis]
18 Ehrlich A, Tsytkin-Kirschenzweig S, Ioannidis K, Ayyash M, Riu A, Note R, Ouedraogo G, Vanfleteren J, Cohen M, Nahmias Y. Microphysiological flux balance platform unravels the dynamics of drug induced steatosis. Lab Chip 2018;18:2510-22. [PMID: 29992215 DOI: 10.1039/c8lc00357b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, Gonzàlez X, Adrover E, Azaro A, Valls-Margarit M, Parra JL, Aguilar J, Vidal M, Martín A, Gavilá J, Escrivá-de-Romaní S, Perelló A, Hernando C, Lahuerta A, Zamora P, Reyes V, Alcalde M, Masanas H, Céliz P, Ruíz I, Gil M, Seguí MÀ, de la Peña L. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol 2019;11:1758835919833867. [PMID: 31205497 DOI: 10.1177/1758835919833867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
20 Risi R, Tuccinardi D, Mariani S, Lubrano C, Manfrini S, Donini LM, Watanabe M. Liver disease in obesity and underweight: the two sides of the coin. A narrative review. Eat Weight Disord 2020. [PMID: 33150534 DOI: 10.1007/s40519-020-01060-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Jain S, Norinder U, Escher SE, Zdrazil B. Combining In Vivo Data with In Silico Predictions for Modeling Hepatic Steatosis by Using Stratified Bagging and Conformal Prediction. Chem Res Toxicol 2021;34:656-68. [PMID: 33347274 DOI: 10.1021/acs.chemrestox.0c00511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Li S, He N, Wang L. Efficiently Anti-Obesity Effects of Unsaturated Alginate Oligosaccharides (UAOS) in High-Fat Diet (HFD)-Fed Mice. Mar Drugs 2019;17:E540. [PMID: 31533255 DOI: 10.3390/md17090540] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
23 Veronese N, Cooper C, Reginster JY, Hochberg M, Branco J, Bruyère O, Chapurlat R, Al-Daghri N, Dennison E, Herrero-Beaumont G, Kaux JF, Maheu E, Rizzoli R, Roth R, Rovati LC, Uebelhart D, Vlaskovska M, Scheen A. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019;49:9-19. [PMID: 30712918 DOI: 10.1016/j.semarthrit.2019.01.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
24 Bucher S, Le Guillou D, Allard J, Pinon G, Begriche K, Tête A, Sergent O, Lagadic-Gossmann D, Fromenty B. Possible Involvement of Mitochondrial Dysfunction and Oxidative Stress in a Cellular Model of NAFLD Progression Induced by Benzo[a]pyrene/Ethanol CoExposure. Oxid Med Cell Longev 2018;2018:4396403. [PMID: 30147834 DOI: 10.1155/2018/4396403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
25 Wang Q, Huang A, Wang JB, Zou Z. Chronic Drug-Induced Liver Injury: Updates and Future Challenges. Front Pharmacol 2021;12:627133. [PMID: 33762948 DOI: 10.3389/fphar.2021.627133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 McGill MR, Jaeschke H. Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation. Expert Rev Mol Diagn 2018;18:797-807. [PMID: 30080986 DOI: 10.1080/14737159.2018.1508998] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
27 Bucher S, Tête A, Podechard N, Liamin M, Le Guillou D, Chevanne M, Coulouarn C, Imran M, Gallais I, Fernier M, Hamdaoui Q, Robin MA, Sergent O, Fromenty B, Lagadic-Gossmann D. Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo. Sci Rep 2018;8:5963. [PMID: 29654281 DOI: 10.1038/s41598-018-24403-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
28 Li X, Gao P, Niu J. Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury. Biomed Res Int 2019;2019:8764093. [PMID: 31531370 DOI: 10.1155/2019/8764093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
29 Worland T, Chin KL, van Langenberg D, Garg M, Nicoll A. Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: the IDLE study. Ann Gastroenterol 2020;33:162-9. [PMID: 32127737 DOI: 10.20524/aog.2020.0453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, Raguz-Lucic N, Wu GY, Smolic M. Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. J Clin Transl Hepatol 2021;9:731-7. [PMID: 34722188 DOI: 10.14218/JCTH.2020.00091] [Reference Citation Analysis]
31 Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat 2019;15:2087-99. [PMID: 31413575 DOI: 10.2147/NDT.S208061] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
32 Liu YH, Guo Y, Xu H, Feng H, Chen DY. Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. Infect Drug Resist 2021;14:3667-71. [PMID: 34526786 DOI: 10.2147/IDR.S326386] [Reference Citation Analysis]
33 Cappe M, Hantson P, Komuta M, Vincent MF, Laterre PF, Ould-Nana I. Hyperammonemic Encephalopathy and Lipid Dysmetabolism in a Critically Ill Patient After a Short Course of Amiodarone. J Crit Care Med (Targu Mures) 2019;5:161-5. [PMID: 31915724 DOI: 10.2478/jccm-2019-0026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]